Why we do need a heightened index of suspicion for recognizing patients who may have NTM lung disease? And what have we learned about epidemiology, transmission, biofilm formation, exposure patterns, and clinical signatures for MAC?

Why we do need a heightened index of suspicion for recognizing patients who may have NTM lung disease? And what have we learned about epidemiology, transmission, biofilm formation, exposure patterns, and clinical signatures for MAC?

Why we do need to have a heightened index of suspicion for recognizing patients who may have NTM lung disease? And what have we learned about epidemiology, transmission, biofilm formation, exposure patterns, and clinical signatures for MAC, that help us identify patients with NTM infection? 


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | NTM-Pulmonary Infection Intelligence Zone

Presenter

Stephen Ruoss, MD

Stephen Ruoss, MD

Clinical Chief, Pulmonary and Critical Care Medicine Division Department of Medicine Medical Director, Stanford Medical Center Respiratory Care Services, Stanford Medical Center Medical Director, Stanford Medical Center Transfer Center, Stanford Univer